« Previous
Next »
Titles
- Alternative pricing models for remdesivir and other potential treatments for COVID-191
- Digital health technologies as an adjunct to medication assisted therapy for opioid use disorder: final evidence report and meeting summary1
- Gene therapies for sickle cell disease: final evidence report1
- JAK inhibitors and monoclonal antibodies for the treatment of atopic dermatitis: effectiveness and value : final evidence report1
- Mepolizumab (Nucala??, GlaxoSmithKline plc.) for the treatment of severe asthma with eosinophilia: effectiveness, value, and value-based price benchmarks : final report1
- Oral and monoclonal antibody treatments for relapsing forms of multiple sclerosis: effectiveness and value : final evidence report1
- Special assessment of outpatient treatments for COVID-19: nirmatrelvir/ritonavir (Paxlovid) health-benefit price benchmark update1
- Tezepelumab for severe asthma: final report1
- Treatments for anemia in chronic kidney disease: effectiveness and value : final evidence report1